DPPA3 and liver cancer: Therefore, inhibiting PGC7/GLI1/MYCN may reverse the poorly differentiated hepatoma cells, inducing a potential therapeutic strategy of differentiated-inducing therapy in patients with liver cancer (Yan et al., 2021).